Joint (NASDAQ:JYNT) Posts Earnings Results, Beats Estimates By $0.02 EPS

Joint (NASDAQ:JYNT) announced its quarterly earnings data on Thursday. The company reported $0.07 EPS for the quarter, beating the consensus estimate of $0.05 by $0.02, FiscalAI reports. The firm had revenue of $15.17 million during the quarter, compared to analysts’ expectations of $14.12 million. Joint had a negative net margin of 1.78% and a negative return on equity of 0.98%.

Here are the key takeaways from Joint’s conference call:

• The company has materially advanced its refranchising program—reducing corporate clinics from 135 to 48, signing an asset purchase agreement for 22 clinics and an LOI for five more—and expects to complete the transition to a pure-play franchisor by mid-2026, which management says will improve operating leverage.
• Profitability and capital returns improved: Q4 consolidated adjusted EBITDA rose 7.8% (to $3.6M) and full-year adjusted EBITDA rose 13.9% to $13M, consolidated net income turned positive to $2.9M, cash was $23.6M, and the company repurchased 1.3M shares for $11.3M in 2025.
• Near-term demand remains a headwind as Q4 system-wide sales fell 3.9% and comp sales fell 3.8%, with management identifying new patient acquisition as the weakest component; marketing/SEO investments show early signs of improvement but 2026 comp guidance is a wide -3% to +3% range.
• Management laid out a post-refranchising run-rate model targeting ~11% revenue as a franchisor, with an estimated adjusted EBITDA margin of 19%–21% (vs. 12% in 2025), net income margin of 13%–15%, and 60%–70% free-cash-flow conversion, signaling materially higher margins if assumptions are met.

Joint Stock Up 4.3%

Shares of Joint stock traded up $0.35 on Friday, hitting $8.56. The company’s stock had a trading volume of 26,130 shares, compared to its average volume of 58,227. Joint has a 52-week low of $7.50 and a 52-week high of $13.47. The firm has a fifty day moving average price of $9.28 and a 200-day moving average price of $9.11. The company has a market capitalization of $127.29 million, a P/E ratio of -142.64 and a beta of 1.33.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Joint in a report on Thursday, January 22nd. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $17.00.

Insiders Place Their Bets

In other Joint news, major shareholder Charles E. Jobson bought 16,753 shares of the company’s stock in a transaction on Friday, January 23rd. The stock was purchased at an average cost of $10.00 per share, for a total transaction of $167,530.00. Following the acquisition, the insider owned 1,638,424 shares of the company’s stock, valued at $16,384,240. The trade was a 1.03% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. In the last ninety days, insiders have bought 37,849 shares of company stock worth $348,981. Company insiders own 27.90% of the company’s stock.

Institutional Trading of Joint

Several large investors have recently modified their holdings of JYNT. BNP Paribas Financial Markets raised its position in shares of Joint by 104.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,935 shares of the company’s stock worth $28,000 after purchasing an additional 1,501 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in Joint by 32.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 7,412 shares of the company’s stock valued at $86,000 after buying an additional 1,810 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Joint by 25.9% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 8,244 shares of the company’s stock valued at $95,000 after buying an additional 1,698 shares during the last quarter. XTX Topco Ltd purchased a new position in Joint during the fourth quarter worth $124,000. Finally, Wells Fargo & Company MN increased its position in Joint by 78.0% during the fourth quarter. Wells Fargo & Company MN now owns 15,476 shares of the company’s stock worth $135,000 after buying an additional 6,784 shares in the last quarter. 76.88% of the stock is currently owned by institutional investors and hedge funds.

About Joint

The Joint Chiropractic, Inc, doing business as Joint (NASDAQ: JYNT), is a franchisor and operator of outpatient chiropractic clinics in the United States. Under its flagship The Joint Chiropractic brand, the company offers membership-based, cash-focused spinal adjustment services designed to promote accessible, routine care for neck and back discomfort. By removing insurance requirements and offering walk-in visits, Joint aims to streamline the patient experience and reduce cost barriers to ongoing chiropractic treatment.

Joint’s growth strategy centers on partnering with franchisees to expand its network of clinics.